{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:23:42Z","timestamp":1793766222972,"version":"4.6.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002951","name":"Daniel and Florence Guggenheim Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002951","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/09868-7"],"award-info":[{"award-number":["2018\/09868-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["IDs 2019\/25936-5"],"award-info":[{"award-number":["IDs 2019\/25936-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["88881.068515\/2014-01"],"award-info":[{"award-number":["88881.068515\/2014-01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["ID 303753\/2015-3"],"award-info":[{"award-number":["ID 303753\/2015-3"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.biopha.2020.111138","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T21:25:09Z","timestamp":1608153909000},"page":"111138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["4-Aminoquinoline compounds from the Spanish flu to COVID-19"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-7913","authenticated-orcid":false,"given":"Roberto Barbosa","family":"Bazotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-0444","authenticated-orcid":false,"given":"Sandro Massao","family":"Hirabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamires Afonso Duarte","family":"Serdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-7922","authenticated-orcid":false,"given":"Raquel Bragante","family":"Gritte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0317-5052","authenticated-orcid":false,"given":"Talita","family":"Souza-Siqueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Gorjao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laureane Nunes","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4728-8518","authenticated-orcid":false,"given":"Marina Masetto","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Cruzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania Cristina","family":"Pithon-Curi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Curi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jdermsci.2007.05.009","article-title":"Antiviral effects of quinine sulfate on HSV-1 HaCat cells infected: analysis of the molecular mechanisms involved","volume":"47","author":"Baroni","year":"2007","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.biopha.2020.111138_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.virusres.2018.07.018","article-title":"Drug repurposing of quinine as antiviral against dengue virus infection","volume":"255","author":"Malakar","year":"2018","journal-title":"Virus Res."},{"issue":"3\u20134","key":"10.1016\/j.biopha.2020.111138_bib0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.vetmic.2015.02.007","article-title":"Antiviral effect of mefloquine on feline calicivirus in vitro","volume":"176","author":"McDonagh","year":"2015","journal-title":"Vet. Microbiol."},{"issue":"10","key":"10.1016\/j.biopha.2020.111138_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110631","article-title":"Inhibition of influenza virus replication by targeting broad host cell pathways","volume":"9","author":"Marois","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0025","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.293","article-title":"Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases","volume":"5","author":"Al\u2010Bari","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"issue":"5","key":"10.1016\/j.biopha.2020.111138_bib0030","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/AAC.3.5.537","article-title":"Antiviral activity and induction of interferon-like substance by quinacrine and acranil","volume":"3","author":"Gl\u00e1z","year":"1973","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2020.111138_bib0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/AAC.3.5.537","article-title":"Antiviral activity and induction of interferon-like substance by quinacrine and acranil","volume":"3","author":"Glaz","year":"1973","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/microorganisms8010085","article-title":"The use of antimalarial drugs against viral infection","volume":"8","author":"D\u2019Alessandro","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.biopha.2020.111138_bib0045","series-title":"The Alkaloids: Chemistry and Pharmacology","author":"Cordell","year":"1993"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0050","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.26273","article-title":"The antimalarial ferroquine is an inhibitor of hepatitis C virus","volume":"58","author":"Vausselin","year":"2013","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.biopha.2020.111138_bib0055","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jmv.25440","article-title":"Antimalarial drugs and their metabolites are potent Zika virus inhibitors","volume":"91","author":"Han","year":"2019","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0060","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3390\/v11020176","article-title":"Identification of broad-spectrum antiviral compounds by targeting viral entry","volume":"11","author":"Mazzon","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2020.111138_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101735","article-title":"Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review","author":"Hashem","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106119","article-title":"In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection","volume":"56","author":"Braz","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"15","key":"10.1016\/j.biopha.2020.111138_bib0075","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0080","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1473-3099(06)70361-9","article-title":"New insights into the antiviral effects of chloroquine","volume":"6","author":"Savarino","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2020.111138_bib0085","series-title":"Mechanism of Action of Hydroxychloroquine As an Antirheumatic Drug, Seminars in Arthritis and Rheumatism","first-page":"82","author":"Fox","year":"1993"},{"issue":"8","key":"10.1016\/j.biopha.2020.111138_bib0090","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/0006-2952(65)90295-9","article-title":"Biochemical properties of anti-inflammatory drugs\u2014VI: the effects of chloroquine (resochin), mepacrine (quinacrine) and some of their potential metabolites on cartilage metabolism and oxidative phosphorylation","volume":"14","author":"Whitehouse","year":"1965","journal-title":"Biochem. Pharmacol."},{"issue":"18","key":"10.1016\/j.biopha.2020.111138_bib0095","first-page":"1824","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(83)91265-2","article-title":"Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate","volume":"75","author":"McChesney","year":"1983","journal-title":"Am. J. Med."},{"key":"10.1016\/j.biopha.2020.111138_bib0105","first-page":"1","article-title":"Chloroquine for SARS-CoV-2: implications of its unique pharmacokinetic and safety properties","author":"Smit","year":"2020","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.biopha.2020.111138_bib0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0306-3623(82)90110-0","article-title":"Kinetics of the distribution and elimination of chloroquine in the rat","volume":"13","author":"Adelusi","year":"1982","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111138_bib0115","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.toxrep.2014.10.019","article-title":"Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies","volume":"1","author":"Schroeder","year":"2014","journal-title":"Toxicol. Rep."},{"issue":"1_suppl","key":"10.1016\/j.biopha.2020.111138_bib0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases","volume":"5","author":"Furst","year":"1996","journal-title":"Lupus"},{"issue":"7","key":"10.1016\/j.biopha.2020.111138_bib0125","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.drudis.2020.04.021","article-title":"Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19","volume":"25","author":"D\u2019Acquarica","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1365-2125.1995.tb05768.x","article-title":"Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects","volume":"40","author":"Ducharme","year":"1995","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0135","first-page":"308","article-title":"Antimalarial activity of the optical isomers of chloroquine diphosphate","volume":"30","author":"Haberkorn","year":"1979","journal-title":"Tropenmedizin und Parasitologie"},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-198612000-00014","article-title":"Enantioselective analysis of chloroquine and desethylchloroquine after oral administration of racemic chloroquine","volume":"8","author":"Ofori-Adjei","year":"1986","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0145","first-page":"70","article-title":"Stereochemistry in drug action","volume":"5","author":"McConathy","year":"2003","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"issue":"9209","key":"10.1016\/j.biopha.2020.111138_bib0150","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(00)02047-X","article-title":"Chiral switches","volume":"355","author":"Tucker","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.biopha.2020.111138_bib0155","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/molecules25081834","article-title":"COVID-19, chloroquine repurposing, and cardiac safety concern: chirality might help","volume":"25","author":"Lentini","year":"2020","journal-title":"Molecules"},{"issue":"26","key":"10.1016\/j.biopha.2020.111138_bib0160","doi-asserted-by":"crossref","first-page":"23587","DOI":"10.1074\/jbc.M200448200","article-title":"Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block","volume":"277","author":"S\u00e1nchez-Chapula","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0165","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1073\/pnas.0708153105","article-title":"The molecular basis of chloroquine block of the inward rectifier Kir2. 1 channel","volume":"105","author":"Rodr\u00edguez-Menchaca","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/jat.1395","article-title":"Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs\u2019 cardiotoxic properties","volume":"29","author":"Polak","year":"2009","journal-title":"J. Appl. Toxicol."},{"issue":"28","key":"10.1016\/j.biopha.2020.111138_bib0175","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2174\/092986707782794087","article-title":"Predictive models for HERG channel blockers: ligand-based and structure-based approaches","volume":"14","author":"Thai","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2020.111138_bib0180","first-page":"1","article-title":"A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing","author":"Gordon","year":"2020","journal-title":"bioRxiV (preprint)"},{"issue":"15","key":"10.1016\/j.biopha.2020.111138_bib0185","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.216259","article-title":"Viral escape from endosomes and host detection at a glance","volume":"131","author":"Staring","year":"2018","journal-title":"J. Cell. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.virol.2007.11.001","article-title":"Interactions of LSECtin and DC-SIGN\/DC-SIGNR with viral ligands: differential pH dependence, internalization and virion binding","volume":"373","author":"Gramberg","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2020.111138_bib0195","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","article-title":"Viral membrane fusion","volume":"479","author":"Harrison","year":"2015","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-019-0132-8","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1073\/pnas.86.2.544","article-title":"Regulation of endocytic pH by the Na+, K+-ATPase in living cells","volume":"86","author":"Cain","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5728","key":"10.1016\/j.biopha.2020.111138_bib0215","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1110656","article-title":"Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection","volume":"308","author":"Chandran","year":"2005","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0220","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/AAC.01246-09","article-title":"Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation","volume":"54","author":"Martinson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2020.111138_bib0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.virol.2014.07.025","article-title":"Endosomal acidification and cathepsin L activity is required for calicivirus replication","volume":"464","author":"Shivanna","year":"2014","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.biopha.2020.111138_bib0230","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1042\/BST20140145","article-title":"Lysosomotropic agents: impact on lysosomal membrane permeabilization and cell death","volume":"42","author":"Villamil Giraldo","year":"2014","journal-title":"Biochem. Soc. Trans."},{"issue":"5","key":"10.1016\/j.biopha.2020.111138_bib0235","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1128\/AAC.43.5.1304","article-title":"Synergistic in vitro antimalarial activity of omeprazole and quinine","volume":"43","author":"Skinner-Adams","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0240","first-page":"161","article-title":"A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis","volume":"43","author":"Kochar","year":"2006","journal-title":"J. Vector Borne Dis."},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0245","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1083\/jcb.90.3.656","article-title":"Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances","volume":"90","author":"Ohkuma","year":"1981","journal-title":"J. Cell Biol."},{"issue":"18","key":"10.1016\/j.biopha.2020.111138_bib0250","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","article-title":"Lysosomotropic agents","volume":"23","author":"De Duve","year":"1974","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.111138_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106044","article-title":"Widely available lysosome targeting agents should be considered as a potential therapy for COVID-19","author":"Homolak","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0006-2952(91)90006-Q","article-title":"Kinetics and thermodynamics of chloroquine and hydroxychloroquine transport across the human erythrocyte membrane","volume":"41","author":"Ferrari","year":"1991","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2020.111138_bib0265","doi-asserted-by":"crossref","DOI":"10.5936\/csbj.201308002","article-title":"Autophagy in plasmodium, a multifunctional pathway?","volume":"8","author":"Hain","year":"2013","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"6","key":"10.1016\/j.biopha.2020.111138_bib0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/vbz.2008.0049","article-title":"On chikungunya acute infection and chloroquine treatment","volume":"8","author":"Lamballerie","year":"2008","journal-title":"Vector-Borne Zoonotic Dis."},{"issue":"19\u201320","key":"10.1016\/j.biopha.2020.111138_bib0275","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.drudis.2013.05.002","article-title":"Chikungunya virus: an update on antiviral development and challenges","volume":"18","author":"Kaur","year":"2013","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2020.111138_bib0280","first-page":"17","article-title":"Chikungunya fever\u2013expanded distribution of a re-emerging tropical infectious disease","volume":"32","author":"Stock","year":"2009","journal-title":"Medizinische Monatsschrift fur Pharmazeuten"},{"key":"10.1016\/j.biopha.2020.111138_bib0285","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.6085.2","article-title":"Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry","volume":"4","author":"Long","year":"2015","journal-title":"F1000Research"},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0290","doi-asserted-by":"crossref","first-page":"L270","DOI":"10.1152\/ajplung.00011.2014","article-title":"Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1","volume":"308","author":"Yeganeh","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.biopha.2020.111138_bib0295","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression","author":"Zhou","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2020.111138_bib0300","series-title":"HIDROXICLOROQUINA E CLOROQUINA PARA INFEC\u00c7\u00c3O POR COVID-19","author":"Pacheco","year":"2020"},{"key":"10.1016\/j.biopha.2020.111138_bib0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.111138_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.111138_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","author":"Gautret","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.111138_bib0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101738","article-title":"Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France","author":"Million","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.111138_bib0325","first-page":"1","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv (preprint)"},{"key":"10.1016\/j.biopha.2020.111138_bib0330","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.biopha.2020.111138_bib0335","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jemermed.2020.07.042","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","volume":"59","author":"Rosenberg","year":"2020","journal-title":"J. Emerg. Med."},{"issue":"384","key":"10.1016\/j.biopha.2020.111138_bib0340","first-page":"30085","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","volume":"50","author":"Molina","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"9","key":"10.1016\/j.biopha.2020.111138_bib0345","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0350","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jmcb\/mjaa014","article-title":"Treating COVID-19 with chloroquine","volume":"12","author":"Huang","year":"2020","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2020.111138_bib0355","article-title":"Subcutaneous administration of interferon beta-1a for COVID-19: a non-controlled prospective trial","author":"Dastan","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2020.111138_bib0360","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2016638","article-title":"A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19","author":"Boulware","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2020.111138_bib0365","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf."},{"issue":"12","key":"10.1016\/j.biopha.2020.111138_bib0370","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41584-018-0111-8","article-title":"Hydroxychloroquine retinopathy\u2014Implications of research advances for rheumatology care","volume":"14","author":"Jorge","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0375","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3899\/jrheum.181102","article-title":"Retinal complications in patients with systemic lupus erythematosus treated with antimalarial drugs","volume":"47","author":"Mukwikwi","year":"2020","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2020.111138_bib0380","first-page":"322","article-title":"Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening","volume":"7","author":"Geamnu","year":"2014","journal-title":"Rev. J. Med. Life"},{"key":"10.1016\/j.biopha.2020.111138_bib0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.resconrec.2020.105052","article-title":"Challenges, opportunities, and innovations for effective solid waste management during and post COVID-19 pandemic","volume":"162","author":"Sharma","year":"2020","journal-title":"Resour. Conserv. Recycl."},{"issue":"9","key":"10.1016\/j.biopha.2020.111138_bib0390","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.hrthm.2020.03.024","article-title":"SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes","volume":"17","author":"Wu","year":"2020","journal-title":"Heart Rhythm"},{"issue":"25","key":"10.1016\/j.biopha.2020.111138_bib0395","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2020.111138_bib0400","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2020.111138_bib0405","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"4","key":"10.1016\/j.biopha.2020.111138_bib0410","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"issue":"25","key":"10.1016\/j.biopha.2020.111138_bib0415","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","article-title":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","volume":"382","author":"Geleris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2020.111138_bib0420","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1002\/jmv.26174","article-title":"Clinical characteristics of COVID-19 in patients with preexisting ILD: a retrospective study in a single center in Wuhan, China","volume":"92","author":"Huang","year":"2020","journal-title":"J. Med. Virol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220313317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:30:27Z","timestamp":1779449427000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220313317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":84,"alternative-id":["S0753332220313317"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111138","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-Aminoquinoline compounds from the Spanish flu to COVID-19","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.111138","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111138"}}